Abstract | PURPOSE: METHODS: RESULTS: Eighty-one patients were included; 24, 31 and 26 patients in groups A, B and C, respectively. Pretreatment hypogonadism prevalence was 75.0, 93.5 and 90.9% (p = 0.046; A vs B and C), central hypocortisolism - 0, 6.9 and 33.3% (p = 0.005), and central hypothyroidism - 6.7, 17.9 and 26.1% (NS) in groups A, B and C, respectively. Only 26.7% of all patients presented with hypocortisolism and/or hypothyroidism (42.9% in group C). Anemia (Hb < 13.5 g%) was detected in 31.3, 57.1 and 80.0% in groups A, B and C, respectively (p = 0.04). Larger adenoma diameter correlated strongly with lower FT4 levels following treatment (r = -0.42, p = 0.043). CONCLUSIONS:
|
Authors | Amit Tirosh, Carlos Benbassat, Avner Lifshitz, Ilan Shimon |
Journal | Pituitary
(Pituitary)
Vol. 18
Issue 1
Pg. 108-15
(Feb 2015)
ISSN: 1573-7403 [Electronic] United States |
PMID | 24700366
(Publication Type: Journal Article)
|
Chemical References |
- Ergolines
- Testosterone
- Cabergoline
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Cabergoline
- Ergolines
(therapeutic use)
- Humans
- Hypopituitarism
(blood, drug therapy, epidemiology, etiology)
- Male
- Middle Aged
- Prevalence
- Prolactinoma
(blood, complications, drug therapy, epidemiology)
- Retrospective Studies
- Testosterone
(blood)
- Young Adult
|